- Home
- CULP vs MAIA Comparison
CULP vs MAIA Comparison
Compare CULP & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CULP
- MAIA
- Stock Information
- Founded
- CULP 1972
- MAIA 2018
- Country
- CULP United States
- MAIA United States
- Employees
- CULP N/A
- MAIA N/A
- Industry
- CULP Textiles
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- CULP Consumer Discretionary
- MAIA Health Care
- Exchange
- CULP Nasdaq
- MAIA Nasdaq
- Market Cap
- CULP 52.7M
- MAIA 44.9M
- IPO Year
- CULP N/A
- MAIA 2022
- Fundamental
- Price
- CULP $3.94
- MAIA $1.05
- Analyst Decision
- CULP
- MAIA
- Analyst Count
- CULP 0
- MAIA 0
- Target Price
- CULP N/A
- MAIA N/A
- AVG Volume (30 Days)
- CULP 15.6K
- MAIA 690.5K
- Earning Date
- CULP 12-03-2025
- MAIA 11-07-2025
- Dividend Yield
- CULP N/A
- MAIA N/A
- EPS Growth
- CULP N/A
- MAIA N/A
- EPS
- CULP N/A
- MAIA N/A
- Revenue
- CULP $207,391,000.00
- MAIA N/A
- Revenue This Year
- CULP $1.93
- MAIA N/A
- Revenue Next Year
- CULP $2.77
- MAIA N/A
- P/E Ratio
- CULP N/A
- MAIA N/A
- Revenue Growth
- CULP N/A
- MAIA N/A
- 52 Week Low
- CULP $3.42
- MAIA $0.98
- 52 Week High
- CULP $5.94
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- CULP 40.60
- MAIA 32.78
- Support Level
- CULP $3.86
- MAIA $0.98
- Resistance Level
- CULP $4.03
- MAIA $1.16
- Average True Range (ATR)
- CULP 0.11
- MAIA 0.09
- MACD
- CULP -0.01
- MAIA -0.01
- Stochastic Oscillator
- CULP 32.29
- MAIA 8.90
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.